AbbVie ABROAD (Phase 2)

Back to Drug Development Trials
Drug Development Trials

About the trial

WA only

ABBV-552 is a modulator of synaptic vesicle glycoprotein 2A (SV2A), which is a protein expressed in virtually all synapses in the brain and known to play a role in regulating neurotransmitter release. Given that synaptic loss is the major neurobiological correlate of cognitive deficits of Alzheimer’s disease, ABBV-552, through direct modulation of synaptic function, is expected to improve cognitive performance.

Who can be involved:

  • Male or female, aged 50 – 90 years inclusive, at the time of informed consent
  • Must be diagnosed with Mild Cognitive Impairment (MCI) or mild Alzheimer’s disease
  • Have an identified, reliable, study partner
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening

What is involved:

  • Week 1, 2, 6, 12, safety follow-up (7 site visits) + 4 telephone call visits
  • 3 months trial duration
  • Oral tablet once a day
  • Must be able to tolerate MRI scans
  • 25% chance of receiving a placebo

Additional info:

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: 

* Please note that participants in this study may have a chance of being placed on a placebo medication